{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:12:19Z","timestamp":1789744339778,"version":"4.0.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic and targeted immune-modulating agents are increasingly used to manage autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. As more patients receiving these therapies undergo elective breast augmentation and implant-based reconstruction, the effect of biologic exposure on postoperative outcomes remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated whether preoperative use of biologic or immune-modulating agents is associated with increased complications following reconstructive and aesthetic breast surgery procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort analysis was performed using the TriNetX database. Patients who underwent breast reconstruction or augmentation were identified by Current Procedural Terminology codes and stratified by preoperative exposure to biologic or immune-modulating agents within 6 months of surgery. Agents included tumor necrosis factor-\u03b1, interleukin, Janus kinase, mammalian target of rapamycin, and calcineurin inhibitors, among others. Propensity score matching (1:1) controlled for demographic and clinical covariates. Postoperative complications were assessed at 30 days, 90 days, and 6 months and included wound dehiscence, infection, seroma or hematoma, implant revision, and hospital readmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 211,105 patients, 4024 had biologic exposure and 207,081 were controls. After propensity score matching, 3980 patients remained in each cohort. Complication rates were comparable between groups at all timepoints (P &amp;gt; .05). Biologic exposure was not associated with increased risk of wound, infectious, implant revision, or hospital readmission complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preoperative biologic or immune-modulating therapy was not associated with a significant increase in postoperative surgical complications after breast reconstruction or augmentation procedures. Continuing these therapies in appropriate patients appears safe and may reduce unnecessary treatment interruptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence: 3 (Therapeutic)<\/jats:title>\n                    <jats:p>For image description, please refer to the figure legend and surrounding text.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/asj\/sjag112","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:27:21Z","timestamp":1781612841000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of Biologic and Immune-modulating Agents in Breast Surgery Procedures: A Retrospective Cohort Analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8004-0850","authenticated-orcid":false,"given":"Aneeq S","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5621-9568","authenticated-orcid":false,"given":"William","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarifa H","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-3132","authenticated-orcid":false,"given":"Marco F","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-6483","authenticated-orcid":false,"given":"Robert D","family":"Galiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026091810565666700_sjag112-B1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","article-title":"Risk of inflammatory central nervous system diseases after tumor necrosis factor\u2013inhibitor treatment for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Xie","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026091810565666700_sjag112-B2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/annrheumdis-2019-216802","article-title":"Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic, and cardiac surgery","volume":"79","author":"George","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026091810565666700_sjag112-B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.prs.0001125128.08298.ca","article-title":"2024 ASPS procedural statistics release","volume":"156","author":"American Society of Plastic Surgeons","year":"2025","journal-title":"Plast Reconstr Surg"},{"key":"2026091810565666700_sjag112-B4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1524-475X.2011.00748.x","article-title":"Tumor necrosis factor-alpha (TNF-\u03b1) is a therapeutic target for impaired cutaneous wound healing","volume":"20","author":"Ashcroft","year":"2012","journal-title":"Wound Repair Regen"},{"key":"2026091810565666700_sjag112-B5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/archsurg.133.5.558","article-title":"Revisiting the role of tumor necrosis factor \u03b1 and the response to surgical injury and inflammation","volume":"133","author":"Ksontini","year":"1998","journal-title":"Arch Surg"},{"key":"2026091810565666700_sjag112-B6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/asj\/sjae241","article-title":"Semaglutide and postoperative outcomes in nondiabetic patients following body contouring surgery","volume":"45","author":"Lewis","year":"2025","journal-title":"Aesthet Surg J"},{"key":"2026091810565666700_sjag112-B7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/asj\/sjae085","article-title":"Prevalence patterns of \\body contouring procedures among injectable glucagon-like peptide-1 receptor agonist users","volume":"44","author":"Toms","year":"2024","journal-title":"Aesthet Surg J"},{"key":"2026091810565666700_sjag112-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bjps.2019.09.038","article-title":"Pre-, intra-, and\/or postoperative arterial and venous thromboembolism prophylaxis for breast surgery: systematic review and meta-analysis","volume":"73","author":"Klifto","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2026091810565666700_sjag112-B9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bjps.2025.11.037","article-title":"Oral contraceptive pills and reduction mammoplasty: a retrospective cohort analysis","volume":"113","author":"Reese","year":"2026","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2026091810565666700_sjag112-B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bjps.2023.05.007","article-title":"Association of preoperative opioid use and postoperative complications following breast reconstruction","volume":"83","author":"Cheah","year":"2023","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2026091810565666700_sjag112-B11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bjps.2025.11.013","article-title":"Perioperative cannabis use on postoperative pain in immediate alloplastic breast reconstruction","volume":"113","author":"Qin","year":"2026","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2026091810565666700_sjag112-B12","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000012703","article-title":"Impact of GLP-1 agonist on surgical wound complications following plastic and reconstructive surgery: a propensity matched cohort large database analysis","author":"Lee","year":"2025","journal-title":"Plast Reconstr Surg"},{"key":"2026091810565666700_sjag112-B13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bjps.2025.07.042","article-title":"Do disease-modifying anti-rheumatic drugs affect implant-based breast reconstruction outcomes in patients with autoimmune connective tissue disease?","volume":"109","author":"Fung","year":"2025","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2026091810565666700_sjag112-B14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.semarthrit.2015.01.008","article-title":"Rheumatoid arthritis: perioperative management of biologics and DMARDs","volume":"44","author":"Goodman","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026091810565666700_sjag112-B15","doi-asserted-by":"publisher","DOI":"10.1177\/01455613241275257","article-title":"The role of immunosuppression on postoperative outcomes in facial fracture repair","author":"Eberly","year":"2024","journal-title":"Ear Nose Throat J"},{"key":"2026091810565666700_sjag112-B16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2106\/JBJS.21.00811","article-title":"The effect of perioperative biologic disease-modifying anti-rheumatic drugs on the risk of postoperative complications: surgical site infection, delayed wound healing, and disease flares following orthopaedic surgical procedures","volume":"104","author":"Van Duren","year":"2022","journal-title":"J Bone Joint Surg Am"},{"key":"2026091810565666700_sjag112-B17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/lary.31774","article-title":"Impact of biologics on surgery in chronic rhinosinusitis with polyps and allergic fungal sinusitis","volume":"135","author":"Bentan","year":"2025","journal-title":"Laryngoscope"},{"key":"2026091810565666700_sjag112-B18","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.arth.2017.05.001","article-title":"2017 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"32","author":"Goodman","year":"2017","journal-title":"J Arthroplasty"},{"key":"2026091810565666700_sjag112-B19","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.arth.2022.05.043","article-title":"2022 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"37","author":"Goodman","year":"2022","journal-title":"J Arthroplasty"},{"key":"2026091810565666700_sjag112-B20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4212\/cjhp.v73i3.3001","article-title":"Practical guidance in perioperative management of immunosuppressive therapy for rheumatology patients undergoing elective surgery","volume":"73","author":"Boyce","year":"2020","journal-title":"Can J Hosp Pharm"},{"key":"2026091810565666700_sjag112-B21","doi-asserted-by":"publisher","first-page":"251.e1","DOI":"10.1016\/j.jaad.2024.03.008","article-title":"Full Guidelines\u2014From the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis","volume":"91","author":"James","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026091810565666700_sjag112-B22","doi-asserted-by":"publisher","first-page":"e3385","DOI":"10.1097\/GOX.0000000000003385","article-title":"Comparing surgical site occurrences in 1 versus 2-stage breast reconstruction via federated EMR network","volume":"9","author":"Singh","year":"2021","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2026091810565666700_sjag112-B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026091810565666700_sjag112-B24","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s10067-025-07668-6","article-title":"Association between rheumatoid arthritis and thyroid cancer risk: a real-world cohort study using TriNetX","volume":"44","author":"Lai","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026091810565666700_sjag112-B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/gastro\/goz004","article-title":"Surgery in the age of biologics","volume":"7","author":"Wong","year":"2019","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026091810565666700_sjag112-B26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000438955","article-title":"Indications and specific surgical techniques in Crohn's disease","volume":"31","author":"Seifarth","year":"2015","journal-title":"Visc Med"},{"key":"2026091810565666700_sjag112-B27","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.3390\/jcm10194402","article-title":"Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of Geteccu","volume":"10","author":"Garc\u00eda","year":"2021","journal-title":"J Clin Med"},{"key":"2026091810565666700_sjag112-B28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/DCR.0000000000003550","article-title":"Biologic therapy is associated with improved oncologic outcomes in Crohn's disease\u2013associated colorectal cancer","volume":"68","author":"Giri","year":"2025","journal-title":"Dis Colon Rectum"},{"key":"2026091810565666700_sjag112-B29","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/DCR.0000000000003222","article-title":"Impact of biologics and small molecule agents on postoperative complications in inflammatory bowel disease: a systematic review","volume":"67","author":"Lee","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"2026091810565666700_sjag112-B30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.24976\/Discov.Med.202537194.37","article-title":"Biological therapy and oral surgery: safety recommendations and practices","volume":"37","author":"Dinkova","year":"2025","journal-title":"Discov Med"},{"key":"2026091810565666700_sjag112-B31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/SAP.0000000000002105","article-title":"Factors affecting healing in the treatment of hidradenitis suppurativa","volume":"84","author":"Worden","year":"2020","journal-title":"Ann Plast Surg"},{"key":"2026091810565666700_sjag112-B32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/apt.12313","article-title":"Meta-analysis: peri-operative anti-TNF\u03b1 treatment and post-operative complications in patients with inflammatory bowel disease","volume":"37","author":"Narula","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2026091810565666700_sjag112-B33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/biomedicines13051232","article-title":"Optimizing biologic therapy for the prevention of post-operative recurrence in Crohn's disease: current evidence and future perspectives","volume":"13","author":"Aljabri","year":"2025","journal-title":"Biomedicines"},{"key":"2026091810565666700_sjag112-B34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026091810565666700_sjag112-B35","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1592\/phco.2005.25.11.1566","article-title":"Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing","volume":"25","author":"Busti","year":"2005","journal-title":"Pharmacotherapy"},{"key":"2026091810565666700_sjag112-B36","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","article-title":"Biologics versus JAK inhibitors. Part II: risk of infections. A narrative review","volume":"14","author":"Mansilla-Polo","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026091810565666700_sjag112-B37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/ALN.0000000000004141","article-title":"Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome","volume":"136","author":"Bosch","year":"2022","journal-title":"Anesthesiology"},{"key":"2026091810565666700_sjag112-B38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/OARRR.S523778","article-title":"Impact of biological therapies on quality of life in rheumatoid arthritis: a narrative review","volume":"17","author":"Mamasaidov","year":"2025","journal-title":"Open Access Rheumatol"},{"key":"2026091810565666700_sjag112-B39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/curroncol32030154","article-title":"Perioperative drug management of systemic therapies in breast cancer: a literature review and treatment recommendations","volume":"32","author":"Galuia","year":"2025","journal-title":"Current Oncology"},{"key":"2026091810565666700_sjag112-B40","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026091810565666700_sjag112-B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104683","article-title":"How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: balancing oncologic benefit and surgical safety","volume":"85","author":"Cazenave","year":"2026","journal-title":"Breast"},{"key":"2026091810565666700_sjag112-B42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026091810565666700_sjag112-B43","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1097\/DCR.0000000000001716","article-title":"The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the surgical management of Crohn's disease","volume":"63","author":"Lightner","year":"2020","journal-title":"Dis Colon Rectum"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag112\/68568690\/sjag112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag112\/68568690\/sjag112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:57:03Z","timestamp":1789743423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/advance-article\/doi\/10.1093\/asj\/sjag112\/8712898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1093\/asj\/sjag112","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"sjag112"}}